The stock of ImmunityBio Inc (IBRX) has gone up by 3.20% for the week, with a 26.18% rise in the past month and a -42.73% drop in the past quarter. The volatility ratio for the week is 11.27%, and the volatility levels for the past 30 days are 10.52% for IBRX. The simple moving average for the past 20 days is 10.05% for IBRX’s stock, with a -33.55% simple moving average for the past 200 days.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
The 36-month beta value for IBRX is at 0.82. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IBRX is 75.81M, and currently, shorts hold a 71.94% of that float. The average trading volume for IBRX on February 03, 2025 was 6.07M shares.
IBRX) stock’s latest price update
ImmunityBio Inc (NASDAQ: IBRX)’s stock price has gone decline by -6.37 in comparison to its previous close of 3.45, however, the company has experienced a 3.20% increase in its stock price over the last five trading days. businesswire.com reported 2025-01-29 that CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne Medicines, Ltd.), a global oncology company, to conduct a confirmatory randomized Phase 3 clinical trial (ResQ201A-NSCLC), combining BeiGene’s tislelizumab, a PD-1 checkpoint inhibitor (CPI), and ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-pmln). The Phase 3 ResQ201A-NSCLC study (NCT06745908) aims to co.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with BTIG Research repeating the rating for IBRX by listing it as a “Buy.” The predicted price for IBRX in the upcoming period, according to BTIG Research is $6 based on the research report published on January 10, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $4, previously predicting the price at $10. The rating they have provided for IBRX stocks is “Neutral” according to the report published on May 12th, 2023.
Jefferies gave a rating of “Buy” to IBRX, setting the target price at $8 in the report published on August 03rd of the previous year.
IBRX Trading at -7.22% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.32% of loss for the given period.
Volatility was left at 10.52%, however, over the last 30 days, the volatility rate increased by 11.27%, as shares surge +24.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.23% lower at present.
During the last 5 trading sessions, IBRX rose by +2.08%, which changed the moving average for the period of 200-days by -35.06% in comparison to the 20-day moving average, which settled at $2.93. In addition, ImmunityBio Inc saw 26.18% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -49.0 for the present operating margin
- -0.24 for the gross margin
The net margin for ImmunityBio Inc stands at -80.17. The total capital return value is set at -1.18.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated -594.33 points at debt to capital in total, while cash flow to debt ratio is standing at -0.57. The debt to equity ratio resting at -1.0. The interest coverage ratio of the stock is -2.41.
Currently, EBITDA for the company is -436.18 million with net debt to EBITDA at -1.5. When we switch over and look at the enterprise to sales, we see a ratio of 411.7. The receivables turnover for the company is 1.76for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.68.
Conclusion
In conclusion, ImmunityBio Inc (IBRX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
